Ikena Oncology, Inc. (IKNA): Price and Financial Metrics

Ikena Oncology, Inc. (IKNA): $3.57

-0.13 (-3.51%)

POWR Rating

Component Grades













Add IKNA to Watchlist
Sign Up

Industry: Biotech



in industry

IKNA Stock Price Chart Interactive Chart >

Price chart for IKNA

IKNA Price/Volume Stats

Current price $3.57 52-week high $21.18
Prev. close $3.70 52-week low $2.83
Day low $3.39 Volume 101,600
Day high $3.77 Avg. volume 158,112
50-day MA $5.57 Dividend yield N/A
200-day MA $10.35 Market Cap 128.91M

Ikena Oncology, Inc. (IKNA) Company Bio

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

IKNA Latest News Stream

Event/Time News Detail
Loading, please wait...

IKNA Latest Social Stream

Loading social stream, please wait...

View Full IKNA Social Stream

Latest IKNA News From Around the Web

Below are the latest news stories about Ikena Oncology Inc that investors may wish to consider to help them evaluate IKNA as an investment opportunity.

Top 10 Stock Picks of Samuel Isaly’s OrbiMed Advisors

In this article, we discuss the top 10 stock picks of Samuel Isaly’s OrbiMed Advisors. If you want to skip our detailed analysis of Isaly’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Samuel Isaly’s OrbiMed Advisors. Samuel Isaly graduated from Princeton University with an A.B. in Economics […]

Yahoo | February 3, 2022

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.D., to its Board of Directors. Dr. Wooster brings more than 30 years of experience in oncology drug discovery and development and dissecting the genetics of cancer and will provide invaluable insight to Ikena as the Company progresses several programs to benefit pat

Yahoo | January 26, 2022

Ikena Oncology (NASDAQ:IKNA) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Ikena Oncology (NASDAQ:IKNA) in a research report sent to investors on Thursday morning, Analyst Ratings Network reports. The brokerage issued a buy rating and a $25.00 target price on the stock. Separately, Zacks Investment Research downgraded shares of Ikena Oncology from a buy rating to a hold rating []

Transcript Daily | December 24, 2021

Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...

New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc.

Yahoo | December 24, 2021

Analysts Offer Insights on Healthcare Companies: HTG Molecular Diagnostics (HTGM), Sol-Gel Technologies (SLGL) and Ikena Oncology (IKNA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HTG Molecular Diagnostics (HTGM – Research Report), Sol-Gel Technologies (SLGL – Research Report) and Ikena Oncology (IKNA – Research Report) with bullish sentiments. HTG Molecular Diagnostics (HTGM) H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics today and set a price target of $9.00. The company's shares closed last Wednesday at $3.70, close to its 52-week low of $3.20. According to TipRanks.

Catie Powers on TipRanks | December 23, 2021

Read More 'IKNA' Stories Here

IKNA Price Returns

1-mo -40.50%
3-mo N/A
6-mo -72.60%
1-year -81.32%
3-year N/A
5-year N/A
YTD -71.53%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.3947 seconds.